In vitro skin penetration of dazmegrel delivered with a bioelastic matrix

International Journal of Pharmaceutics

Volumn 271, Issue 1-2, 2004, Pages 301-303

  Kemppainen, Barbara W ^a   Urry, Dan W ^b,c   Luan, Chi Xiang ^c   Xu, Jie ^c   Swaim, Steven F ^a   Goel, Saryu ^a  

^a AUBURN UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Bioelastics Research Ltd   (United States)

Author keywords

Bioelastic matrix; Dazmegrel; Dermal pressure ulcer; Greyhound dog skin; Skin penetration; Thromboxane synthetase inhibitor

Indexed keywords

DAZMEGREL; DRUG CARRIER; POLYMER; PROTEIN DERIVATIVE; THROMBOXANE SYNTHASE INHIBITOR;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG DELIVERY SYSTEM; DRUG EXPOSURE; DRUG PENETRATION; ELASTICITY; EXCISION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; SKIN PENETRATION; SKIN SURGERY; STATISTICAL SIGNIFICANCE; TIME;

EID: 1142285482     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2003.11.018     Document Type: Article

References (10)

1. Cross P.E., Dickenson R.P., Parry M.J., Randall M.J. Selective thromboxane synthetase inhibitors. 2. 3-(1H-Imidazol-1-ylmetyl)-2-methyl-1H- indole-1-propanoic acid and analogues. J. Med. Chem. 29:1986;1643-1650.
2. Ferreira L.A.M., Doucet J., Seiller M., Grossiod J.L., Marty J.P., Wepierre J. In vitro percutaneous absorption of metronidazole and glucose: comparison of O/W, W/O/W and W/O systems. Int. J. Pharm. 121:1995;169-179.
3. Hawkins G.S. Jr., Reifenrath W.G. Influence of skin source penetration cell fluid and partition coefficient on in vitro skin penetration. J. Pharm. Sci. 75:1986;378-381.
4. Johnson M.E., Blankschtein D., Langer R. Permeation of steroids through human skin. J. Pharm. Sci. 84:1995;1144-1146.
5. Kemppainen, B.W., 1993. Penetration studies with excised human and animal skin. In: Tyson, C.A., Frazier, J.M. (Eds.), In Vitro Biological Systems, vol. 1. Academic Press, San Diego, pp. 504-514.
6. Lorenz R.L., Fischer S., Wober W., Wagner H.A., Weber P.C. Effects on prostanoid formation and pharmacokinetics of dazmegrel (UK-38,485), a novel thromboxane synthetase inhibitor, in man. Biochem. Pharmacol. 35:1986;761-766.
7. Robson, M.C., Heggers, J.P., 1992. Eicosanoids, cytokines, and free radicals. In: Cohen, I.K., Diegelmann, R.F., Linblad, W.J. (Eds.), Wound Healing: Biochemical and Clinical Aspects. W.B. Saunders, Philadelphia, pp. 292-304.
8. Swaim S.F., Bradley D.M., Vaughn D.M., Powers R.D., Hoffman C.E., Beard M.L. Evaluation of thromboxane synthetase inhibitor in the prevention of dermal pressure lesions. Wounds. 6:1994;74-82.
9. Urry, D.W., Nicol, A., Gowda, D.C., Hogan, L.D., McGee, A., Williams, T., Olson, D.B., Cox, B.A., 1993. Medical applications of bioelastic materials. In: Gebelein, C.G. (Ed.), Biotechnological Polymers: Medical, Pharmaceutical and Industrial Applications. Technomic Publishing, Lancaster, PA, pp. 82-103.
10. Wester, R.C., Maibach, H.I., 1985. In vivo animal models for percutaneous absorption. In: Bronaugh, R.L., Maibach, H.I. (Eds.), Percutaneous Absorption. Mechanisms-Methodology-Drug Delivery, vol. 6. Marcel Dekker, New York, pp. 251-266.